On the other hand, PSA has high discrimination power for distinguishing controls from localised cancer before treatment (group D) as well as from metastatic cancers under treatment but cannot distinguish between metastatic hormone-sensitive and metastatic castration-resistant prostate cancers (groups A and B). Here, KLK3 is linked to metastatic malignant neoplasm.